Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories

Schizophrenia Bulletin

Volumn 40, Issue 5, 2014, Pages 1011-1021

  Reilly, James L ^a   Frankovich, Kyle ^b   Hill, Scot ^c   Gershon, Elliot S ^d   Keefe, Richard S E ^e   Keshavan, Matcheri S ^f   Pearlson, Godfrey D ^g,h   Tamminga, Carol A ⁱ   Sweeney, John A ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HARTFORD HOSPITAL   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bipolar disorder; Endophenotype; Family study; Schizoaffective disorder; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; LITHIUM; MOOD STABILIZER;

ACHIEVEMENT TEST; ADULT; ARTICLE; ATTENTION; COGNITIVE DEFECT; ENDOPHENOTYPE; FEMALE; FIRST DEGREE RELATIVE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; NEUROIMAGING; NEUROPHYSIOLOGY; PERSONALITY; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; EXECUTIVE FUNCTION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NUCLEAR FAMILY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; SACCADIC EYE MOVEMENT;

ADULT; BIPOLAR DISORDER; ENDOPHENOTYPES; EXECUTIVE FUNCTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NUCLEAR FAMILY; PSYCHOMOTOR PERFORMANCE; PSYCHOTIC DISORDERS; SACCADES; SCHIZOPHRENIA;

EID: 84907339441     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt132     Document Type: Article

References (63)

1. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160: 636-645.
2. Bearden CE, Freimer NB. Endophenotypes for psychiatric disorders: ready for primetime? Trends Genet. 2006;22: 306-313.
3. Kendler KS, Neale MC. Endophenotype: a conceptual analysis. Mol Psychiatry. 2010;15: 789-797.
4. Preston GA, Weinberger DR. Intermediate phenotypes in schizophrenia: a selective review. Dialogues Clin Neurosci. 2005;7: 165-179.
5. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460: 748-752.
6. Laursen TM, Agerbo E, Pedersen CB. Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index. J Clin Psychiatry. 2009;70: 1432-1438.
7. Lichtenstein P, Yip BH, Björk C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373: 234-239.
8. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002;7: 405-411.
9. Ivleva EI, Morris DW, Moates AF, Suppes T, Thaker GK, Tamminga CA. Genetics and intermediate phenotypes of the schizophrenia-bipolar disorder boundary. Neurosci Biobehav Rev. 2010;34: 897-921.
10. Calkins ME, Iacono WG, Ones DS. Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes. Brain Cogn. 2008;68: 436-461.
11. Calkins ME, Curtis CE, Iacono WG, Grove WM. Antisaccade performance is impaired in medically and psychiatrically healthy biological relatives of schizophrenia patients. Schizophr Res. 2004;71: 167-178.
12. Levy DL, Bowman EA, Abel L, Krastoshevsky O, Krause V, Mendell NR. Does performance on the standard antisaccade task meet the co-familiality criterion for an endophenotype? Brain Cogn. 2008;68: 462-475.
13. Light GA, Swerdlow NR, Rissling AJ, et al. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012;7: e39434.
14. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2007;33: 69-94.
15. Broerse A, Holthausen EA, van den Bosch RJ, den Boer JA. Does frontal normality exist in schizophrenia? A saccadic eye movement study. Psychiatry Res. 2001;103: 167-178.
16. Ettinger U, Kumari V, Crawford TJ, et al. Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. J Psychiatr Res. 2004;38: 177-184.
17. Harris MS, Reilly JL, Keshavan MS, Sweeney JA. Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia. Psychol Med. 2006;36: 485-494.
18. Hutton SB, Ettinger U. The antisaccade task as a research tool in psychopathology: a critical review. Psychophysiology. 2006;43: 302-313.
19. Reilly JL, Harris MS, Khine TT, Keshavan MS, Sweeney JA. Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia. Biol Psychiatry. 2008;63: 776-783.
20. Greenwood TA, Braff DL, Light GA, et al. Initial heritability analyses of endophenotypic measures for schizophrenia: the Consortium on the Genetics of Schizophrenia. Arch Gen Psychiatry. 2007;64: 1242-1250.
21. McDowell JE, Clementz BA. The effect of fixation condition manipulations on antisaccade performance in schizophrenia: studies of diagnostic specificity. Exp Brain Res. 1997;115: 333-344.
22. Curtis CE, Calkins ME, Grove WM, Feil KJ, Iacono WG. Saccadic disinhibition in patients with acute and remitted schizophrenia and their first-degree biological relatives. Am J Psychiatry. 2001;158: 100-106.
23. Curtis CE, Calkins ME, Iacono WG. Saccadic disinhibition in schizophrenia patients and their first-degree biological relatives. A parametric study of the effects of increasing inhibitory load. Exp Brain Res. 2001;137: 228-236.
24. Katsanis J, Kortenkamp S, Iacono WG, Grove WM. Antisaccade performance in patients with schizophrenia and affective disorder. J Abnorm Psychol. 1997;106: 468-472.
25. Thaker GK, Ross DE, Cassady SL, Adami HM, Medoff DR, Sherr J. Saccadic eye movement abnormalities in relatives of patients with schizophrenia. Schizophr Res. 2000;45: 235-244.
26. Petrovsky N, Weiss-Motz F, Schulze-Rauschenbach S, et al. Antisaccade performance is related to genetic loading for schizophrenia. J Psychiatr Res. 2009;43: 291-297.
27. Clementz BA, McDowell JE, Zisook S. Saccadic system functioning among schizophrenia patients and their first-degree biological relatives. J Abnorm Psychol. 1994;103: 277-287.
28. Crawford TJ, Sharma T, Puri BK, Murray RM, Berridge DM, Lewis SW. Saccadic eye movements in families multiply affected with schizophrenia: the Maudsley Family Study. Am J Psychiatry. 1998;155: 1703-1710.
29. de Wilde OM, Bour L, Dingemans P, Boerée T, Linszen D. Antisaccade deficit is present in young first-episode patients with schizophrenia but not in their healthy young siblings. Psychol Med. 2008;38: 871-875.
30. Mazhari S, Price G, Dragovic M, Waters FA, Clissa P, Jablensky A. Revisiting the suitability of antisaccade performance as an endophenotype in schizophrenia. Brain Cogn. 2011;77: 223-230.
31. Price GW, Michie PT, Johnston J, et al. A multivariate electrophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian family study of schizophrenia. Biol Psychiatry. 2006;60: 1-10.
32. Radant AD, Dobie DJ, Calkins ME, et al. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology. 2010;47: 846-856.
33. Raemaekers M, Ramsey NF, Vink M, van den Heuvel MP, Kahn RS. Brain activation during antisaccades in unaffected relatives of schizophrenic patients. Biol Psychiatry. 2006;59: 530-535.
34. Martin LF, Hall MH, Ross RG, Zerbe G, Freedman R, Olincy A. Physiology of schizophrenia, bipolar disorder, and schizoaffective disorder. Am J Psychiatry. 2007;164: 1900-1906.
35. Harris MS, Reilly JL, Thase ME, Keshavan MS, Sweeney JA. Response suppression deficits in treatment-naïve firstepisode patients with schizophrenia, psychotic bipolar disorder and psychotic major depression. Psychiatry Res. 2009;170: 150-156.
36. Gooding DC, Tallent KA. The association between antisaccade task and working memory task performance in schizophrenia and bipolar disorder. J Nerv Ment Dis. 2001;189: 8-16.
37. Tien AY, Ross DE, Pearlson G, Strauss ME. Eye movements and psychopathology in schizophrenia and bipolar disorder. J Nerv Ment Dis. 1996;184: 331-338.
38. Hill SK, Reilly JL, Keefe RSE, et al. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar and Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Study. The Am J Psychiatry 2013.
39. Snitz BE, Macdonald AW 3rd, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006;32: 179-194.
40. Dickinson D, Ragland JD, Gold JM, Gur RC. General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol Psychiatry. 2008;64: 823-827.
41. MacDonald AW 3rd, Carter CS, Flory JD, Ferrell RE, Manuck SB. COMT val158Met and executive control: a test of the benefit of specific deficits to translational research. J Abnorm Psychol. 2007;116: 306-312.
42. Corbetta M, Akbudak E, Conturo TE, et al. A common network of functional areas for attention and eye movements. Neuron. 1998;21: 761-773.
43. Moore T, Fallah M. Control of eye movements and spatial attention. Proc Natl Acad Sci USA. 2001;98: 1273-1276.
44. Funahashi S, Chafee MV, Goldman-Rakic PS. Prefrontal neuronal activity in rhesus monkeys performing a delayed anti-saccade task. Nature. 1993;365: 753-756.
45. Munoz DP, Everling S. Look away: the anti-saccade task and the voluntary control of eye movement. Nat Rev Neurosci. 2004;5: 218-228.
46. Sweeney JA, Luna B, Keedy SK, McDowell JE, Clementz BA. fMRI studies of eye movement control: investigating the interaction of cognitive and sensorimotor brain systems. Neuroimage. 2007;36(suppl 2): T54-T60.
47. Polli FE, Barton JJ, Cain MS, Thakkar KN, Rauch SL, Manoach DS. Rostral and dorsal anterior cingulate cortex make dissociable contributions during antisaccade error commission. Proc Natl Acad Sci USA. 2005;102: 15700-15705.
48. Crawford TJ, Parker E, Solis-Trapala I, Mayes J. Is the relationship of prosaccade reaction times and antisaccade errors mediated by working memory? Exp Brain Res. 2011;208: 385-397.
49. Reilly JL, Harris MS, Keshavan MS, Sweeney JA. Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia. Biol Psychiatry. 2005;57: 145-154.
50. Keefe RS, Harvey PD, Goldberg TE, et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res. 2008;102: 108-115.
51. Tamminga CA, Ivleva EI, Keshavan MS, et al. Clinical phenotypes of psychosis in the Bipolar and Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry. 2013.
52. Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-IV Personality: SIDP-IV. Washington, DC American Psychiatric Press; 1997.
53. First M, Gibbon G, Spitzer R, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition. New York, NY: Biometric Research Division, New York State Psychiatric Institute; 1995.
54. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276.
55. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134: 382-389.
56. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133: 429-435.
57. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67: 255-262.
58. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62: 1198-1211.
59. Beaty TH, Liang KY. Robust inference for variance components models in families ascertained through probands: I. Conditioning on proband's phenotype. Genet Epidemiol. 1987;4: 203-210.
60. Malone SM, Iacono WG. Error rate on the antisaccade task: heritability and developmental change in performance among preadolescent and late-adolescent female twin youth. Psychophysiology. 2002;39: 664-673.
61. Chapman LJ, Chapman JP. The measurement of differential deficit. J Psychiatr Res. 1978;14: 303-311.
62. Gold JM, Dickinson D. "Generalized cognitive deficit" in schizophrenia: overused or underappreciated? Schizophr Bull. 2013;39: 263-265.
63. Green MF, Horan WP, Sugar CA. Has the generalized deficit become the generalized criticism? Schizophr Bull. 2013;39: 257-262.